Indications for implantable cardioverter defibrillator therapy

Abstract

The implantable cardioverter defibrillator (ICD) is now an integral therapy for cardiac patient care. More than 20 years have passed since the first ICD implant. Sudden cardiac death from arrhythmia (ventricular tachycardia and fibrillation) has been significantly decreased because of the use of ICD therapy. Primary treatment trials have shown ICD therapy to be superior to drug therapy. Most of these trials compared ICD therapy with amiodarone or sotalol. Prevention trials have also been completed. Patients with nonsustained ventricular tachycardia, low left ventricular ejection fraction, and coronary artery disease were evaluated with electrophysiology studies. Patients with inducible ventricular arrhythmias were treated with ICD or drug suppression therapy. ICD therapy was superior to drug therapy for prevention of fatal arrhythmias. Ongoing trials include evaluation of ICD therapy for patients with high-risk substrates: congestive heart failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, and repolarization syndromes. Factors such as medication inefficacy/side effects, transvenous ICD implantation and overwhelming mortality benefits have expanded ICD usage beyond the original restrictive guidelines.